New combo therapy aims to fight Hard-to-Treat GIST tumors
NCT ID NCT05152472
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug atezolizumab to the standard drug imatinib can help control advanced gastrointestinal stromal tumors (GIST) that have stopped responding to other treatments. About 110 adults with inoperable or metastatic GIST will be randomly assigned to receive either imatinib alone or imatinib plus atezolizumab. The main goal is to see if the combination slows disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imatinib and atezolizumab
What this could lead to
If it works, this could offer a new treatment option for people with advanced GIST who have run out of standard therapies.
What could go wrong
This is an early phase 2 trial with only 110 participants, so results may not be conclusive. Adding atezolizumab may also increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Poitiers
RECRUITINGPoitiers, 86000, France
Contact Email: •••••@•••••
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
Contact Email: •••••@•••••
-
Centre Eugène Marquis
RECRUITINGRennes, 35042, France
Contact Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, Rhône, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
RECRUITINGLille, 59020, France
Contact Email: •••••@•••••
-
Centre Paul Strauss
NOT_YET_RECRUITINGStrasbourg, 67033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chru Tours
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Robert Debré
RECRUITINGReims, 51090, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de La Timone
RECRUITINGMarseille, 13385, France
Contact Email: •••••@•••••
-
ICANS CHRU de Strasbourg
TERMINATEDStrasbourg, 67200, France
-
Institut Bergonié
RECRUITINGBordeaux, 33076, France
Contact Email: •••••@•••••
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de cancérologie de l'Ouest
RECRUITINGSaint-Herblain, 44805, France
Contact Email: •••••@•••••